A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy

References

• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705. doi:10.3748/wjg.v22.i44.9694
   PubMed Web of Science ®Google Scholar
• Goral V.Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev. 2015;16(14):5619–5624. doi:10.7314/APJCP.2015.16.14.5619
   PubMedGoogle Scholar
• Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J. 2017;23(6):333–342. doi:10.1097/PPO.0000000000000290
   PubMed Web of Science ®Google Scholar
• Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17(5.5):603–605. doi:10.6004/jnccn.2019.5007
   PubMed Web of Science ®Google Scholar
• Sarvepalli D, Rashid MU, Rahman AU, et al. Gemcitabine: a review of chemoresistance in pancreatic cancer. Crit Rev Oncog. 2019;24(2):199–212. doi:10.1615/CritRevOncog.2019031641
   Google Scholar
• Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504. doi:10.3390/ijms20184504
   PubMed Web of Science ®Google Scholar
• Ducreux M, Seufferlein T, Van Laethem JL, et al. Systemic treatment of pancreatic cancer revisited. Semin Oncol. 2019;46(1):28–38. doi:10.1053/j.seminoncol.2018.12.003
   Web of Science ®Google Scholar
• Wang Y, Kuramitsu Y, Baron B, et al. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol. 2017;50(2):606–612. doi:10.3892/ijo.2016.3804
   PubMed Web of Science ®Google Scholar
• Ebrahimi S, Hosseini M, Shahidsales S, et al. Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem. 2017;24(13):1321–1331. doi:10.2174/0929867324666170206142658
   PubMed Web of Science ®Google Scholar
• Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620–1637. doi:10.1021/acs.jmedchem.6b00975
   PubMed Web of Science ®Google Scholar
• Kotha RR, Luthria DL. Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules. 2019;24(16):2930. doi:10.3390/molecules24162930
   PubMed Web of Science ®Google Scholar
• Pescosolido N, Giannotti R, Plateroti AM, Pascarella A, Nebbioso M. Curcumin: therapeutical potential in ophthalmology. Planta Med. 2014;80(4):249–254. doi:10.1055/s-0033-1351074
   PubMed Web of Science ®Google Scholar
• Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014;2014:186864. doi:10.1155/2014/186864
   PubMed Web of Science ®Google Scholar
• Giordano A, Tommonaro G. Curcumin and Cancer. Nutrients. 2019;11(10):2376. doi:10.3390/nu11102376
   PubMed Web of Science ®Google Scholar
• Unlu A, Nayir E, Dogukan Kalenderoglu M, Kirca O, Ozdogan M. Curcumin (Turmeric) and cancer. J BUON. 2016;21(5):1050–1060.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041–1053. doi:10.1517/14656566.7.8.1041
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170(3):365–372. doi:10.1016/j.jconrel.2013.05.041
   PubMed Web of Science ®Google Scholar
• Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther. 2015;9:3767–3777. doi:10.2147/DDDT.S88023
   PubMedGoogle Scholar
• Kim H, Samuel S, Lopez-Casas P, et al. SPARC-independent delivery of Nab-Paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer Xenografts. Mol Cancer Ther. 2016;15(4):680–688. doi:10.1158/1535-7163.MCT-15-0764
   Web of Science ®Google Scholar
• Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D. Macropinocytosis of Nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res. 2017;5(3):182–190. doi:10.1158/2326-6066.CIR-16-0125
   PubMed Web of Science ®Google Scholar
• Giordano G, Pancione M, Olivieri N, et al. Nano albumin bound-paclitaxel in pancreatic cancer: current evidences and future directions. World J Gastroenterol. 2017;23(32):5875–5886. doi:10.3748/wjg.v23.i32.5875
   PubMed Web of Science ®Google Scholar
• Neesse A, Michl P, Tuveson DA, Ellenrieder V. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Z Gastroenterol. 2014;52(4):360–366. doi:10.1055/s-0034-1366002
   Web of Science ®Google Scholar
• Tang Z, Feng W, Yang Y, Wang Q. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies. Drug Des Devel Ther. 2019;13:3281–3290. doi:10.2147/DDDT.S211168
   PubMed Web of Science ®Google Scholar
• Zhu R, Tian Y. Preparation and evaluation of RGD and TAT co-modified docetaxel-loaded liposome. Drug Des Devel Ther. 2017;11:3481–3489. doi:10.2147/DDDT.S149620
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu HY, Zhao H, Wang T. RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment. Onco Targets Ther. 2018;11:5397–5405. doi:10.2147/OTT.S169555
   PubMed Web of Science ®Google Scholar
• Cai W, Geng C, Jiang L, et al. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity. Pharm Dev Technol. 2020;25(5):640–648. doi:10.1080/10837450.2020.1727920
   PubMed Web of Science ®Google Scholar
• Tomita M, Sugi H, Ozawa K, Tsong TY, Yoshimura T. Targeting antigen-specific receptors on B lymphocytes to generate high yields of specific monoclonal antibodies directed against biologically active lower antigenic peptides within presenilin 1. J Immunol Methods. 2001;251(1–2):31–43. doi:10.1016/S0022-1759(01)00299-X
   Web of Science ®Google Scholar
• Yuan L, Cao Y, Luo Q, et al. Pullulan-Based nanoparticle-HSA complex formation and drug release influenced by surface charge. Nanoscale Res Lett. 2018;13(1):317. doi:10.1186/s11671-018-2729-5
   PubMed Web of Science ®Google Scholar